Biomea Fusion, Inc. Operating Income
Biomea Fusion, Inc. (BMEA) reported Operating Income of -$12.77 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-05
- Biomea Fusion, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$12.77M.
- Biomea Fusion, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$12.77M.
- Biomea Fusion, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$11.72M.
- Biomea Fusion, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$20.80M.
- Biomea Fusion, Inc. operating income (loss) for fiscal 2025 was -$83.51M.
- Biomea Fusion, Inc. operating income (loss) for fiscal 2024 was -$144.07M.
- Biomea Fusion, Inc. operating income (loss) for fiscal 2023 was -$126.14M.
- Biomea Fusion, Inc. operating income (loss) for fiscal 2022 was -$83.63M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$12.77M 10-Q · filed 2026-08-05 | -$25.54M 10-Q · filed 2026-08-05 | -$37.26M derived: sum of 3 quarters · filed 2026-08-05 | -$58.06M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$12.77M 10-Q · filed 2026-05-11 | -$24.49M derived: sum of 2 quarters · filed 2026-05-11 | -$45.30M derived: sum of 3 quarters · filed 2026-05-11 | -$66.57M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$11.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$32.52M derived: sum of 2 quarters · filed 2026-03-24 | -$53.80M derived: sum of 3 quarters · filed 2026-08-05 | -$83.51M 10-K · filed 2026-03-24 |
| 2025-09-30 | -$20.80M 10-Q · filed 2025-11-04 | -$42.08M derived: sum of 2 quarters · filed 2026-08-05 | -$71.79M 10-Q · filed 2025-11-04 | -$101.87M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$21.28M 10-Q · filed 2026-08-05 | -$50.99M 10-Q · filed 2026-08-05 | -$81.06M derived: sum of 3 quarters · filed 2026-08-05 | -$115.10M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$29.71M 10-Q · filed 2026-05-11 | -$59.79M derived: sum of 2 quarters · filed 2026-05-11 | -$93.83M derived: sum of 3 quarters · filed 2026-05-11 | -$132.72M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$30.07M 10-K · filed 2025-03-31 | -$64.11M derived: sum of 2 quarters · filed 2025-11-04 | -$103.01M derived: sum of 3 quarters · filed 2025-11-04 | -$144.07M 10-K · filed 2026-03-24 |
| 2024-09-30 | -$34.04M 10-Q · filed 2025-11-04 | -$72.94M derived: sum of 2 quarters · filed 2025-11-04 | -$114.00M 10-Q · filed 2025-11-04 | -$151.32M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | -$38.90M 10-Q · filed 2025-08-05 | -$79.96M 10-Q · filed 2025-08-05 | -$117.28M derived: sum of 3 quarters · filed 2025-08-05 | -$148.40M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | -$41.06M 10-Q · filed 2025-05-05 | -$78.39M derived: sum of 2 quarters · filed 2025-05-05 | -$109.51M derived: sum of 3 quarters · filed 2025-05-05 | -$137.16M derived: sum of 4 quarters · filed 2025-05-05 |
| 2023-12-31 | -$37.33M 10-K · filed 2025-03-31 | -$68.45M derived: sum of 2 quarters · filed 2025-03-31 | -$96.10M derived: sum of 3 quarters · filed 2025-03-31 | -$126.14M 10-K · filed 2026-03-24 |
| 2023-09-30 | -$31.12M 10-K · filed 2025-03-31 | -$58.78M derived: sum of 2 quarters · filed 2025-03-31 | -$88.81M 10-Q · filed 2024-10-29 | -$115.08M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-06-30 | -$27.66M 10-K · filed 2025-03-31 | -$57.69M 10-Q · filed 2024-07-31 | -$83.96M derived: sum of 3 quarters · filed 2025-03-31 | -$107.45M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-03-31 | -$30.03M 10-K · filed 2025-03-31 | -$56.31M derived: sum of 2 quarters · filed 2025-03-31 | -$79.79M derived: sum of 3 quarters · filed 2025-03-31 | -$97.27M derived: sum of 4 quarters · filed 2025-03-31 |
| 2022-12-31 | -$26.28M 10-K · filed 2024-03-28 | -$49.76M derived: sum of 2 quarters · filed 2024-03-28 | -$67.23M derived: sum of 3 quarters · filed 2024-03-28 | -$83.63M 10-K · filed 2025-03-31 |
| 2022-09-30 | -$23.48M 10-K · filed 2024-03-28 | -$40.96M derived: sum of 2 quarters · filed 2024-03-28 | -$57.36M 10-Q · filed 2023-10-30 | -$72.09M derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-06-30 | -$17.47M 10-K · filed 2024-03-28 | -$33.87M 10-Q · filed 2023-07-31 | -$48.61M derived: sum of 3 quarters · filed 2024-03-28 | -$61.25M derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-03-31 | -$16.40M 10-K · filed 2024-03-28 | -$31.14M derived: sum of 2 quarters · filed 2024-03-28 | -$43.77M derived: sum of 3 quarters · filed 2024-03-28 | -$52.21M derived: sum of 4 quarters · filed 2024-03-28 |
| 2021-12-31 | -$14.74M 10-K · filed 2023-03-28 | -$27.38M derived: sum of 2 quarters · filed 2023-03-28 | -$35.81M derived: sum of 3 quarters · filed 2023-03-28 | -$41.67M 10-K · filed 2024-03-28 |
| 2021-09-30 | -$12.64M 10-K · filed 2023-03-28 | -$21.07M derived: sum of 2 quarters · filed 2023-03-28 | -$26.93M 10-Q · filed 2022-11-07 | -$30.43M derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-06-30 | -$8.44M 10-K · filed 2023-03-28 | -$14.29M 10-Q · filed 2022-08-01 | -$17.79M derived: sum of 3 quarters · filed 2023-03-28 | -$18.93M derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-03-31 | -$5.86M 10-K · filed 2023-03-28 | -$9.36M derived: sum of 2 quarters · filed 2023-03-28 | -$10.49M derived: sum of 3 quarters · filed 2023-03-28 | -$10.79M derived: sum of 4 quarters · filed 2023-03-28 |
| 2020-12-31 | -$3.50M 10-K · filed 2022-02-28 | -$4.63M derived: sum of 2 quarters · filed 2022-02-28 | -$4.93M derived: sum of 3 quarters · filed 2022-02-28 | -$5.33M 10-K · filed 2023-03-28 |
| 2020-09-30 | -$1.14M 10-K · filed 2022-02-28 | -$1.43M derived: sum of 2 quarters · filed 2022-02-28 | -$1.83M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | -$295.00K 10-K · filed 2022-02-28 | -$693.00K 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | -$398.00K 10-K · filed 2022-02-28 | |||
| 2019-12-31 | -$1.20M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |